PMID- 22703663
OWN - NLM
STAT- MEDLINE
DCOM- 20121203
LR  - 20220410
IS  - 1878-3554 (Electronic)
IS  - 0099-2399 (Linking)
VI  - 38
IP  - 7
DP  - 2012 Jul
TI  - Mineral trioxide aggregate-based endodontic sealer stimulates hydroxyapatite 
      nucleation in human osteoblast-like cell culture.
PG  - 971-6
LID - 10.1016/j.joen.2012.02.018 [doi]
AB  - INTRODUCTION: The main purpose of this study was to evaluate the biocompatibility 
      and bioactivity of a new mineral trioxide aggregate (MTA)-based endodontic 
      sealer, MTA Fillapex (MTA-F; Angelus, Londrina, Brazil), in human cell culture. 
      METHODS: Human osteoblast-like cells (Saos-2) were exposed for 1, 2, 3, and 7 
      days to MTA-F, Epiphany SE (EP-SE; SybronEndo, Orange, CA), and zinc 
      oxide-eugenol sealer (ZOE). Unexposed cultures were the control group (CT). The 
      viability of the cells was assessed by MTT assay and the morphology by scanning 
      electron microscopy (SEM). The bioactivity of MTA-F was evaluated by alkaline 
      phosphatase activity (ALP) and the detection of calcium deposits in the culture 
      with alizarin red stain (ARS). Energy-dispersive X-ray spectroscopy (EDS) was 
      used to chemically characterize the hydroxyapatite crystallites (HAP). Saos-2 
      cells were cultured for 21 days for ARS and SEM/EDS. ARS results were expressed 
      as the number of stained nodules per area. Statistical analysis was performed 
      with analysis of variance and Bonferroni tests (P < .01). RESULTS: MTA-F exposure 
      for 1, 2, and 3 days resulted in increased cytotoxicity. In contrast, viability 
      increased after 7 days of exposure to MTA-F. Exposure to EP-SE and ZOE was 
      cytotoxic at all time points. At day 7, ALP activity increase was significant in 
      the MTA-F group. MTA-F presented the highest percentage of ARS-stained nodules 
      (MTA-F > CT > EP-SE > ZOE). SEM/EDS analysis showed hydroxyapatite crystals only 
      in the MTA-F and CT groups. In the MTA-F group, crystallite morphology and 
      chemical composition were different from CT. CONCLUSIONS: After setting, the 
      cytotoxicity of MTA-F decreases and the sealer presents suitable bioactivity to 
      stimulate HAP crystal nucleation.
CI  - Copyright (c) 2012 American Association of Endodontists. Published by Elsevier Inc. 
      All rights reserved.
FAU - Salles, Loise Pedrosa
AU  - Salles LP
AD  - Department of Restorative Dentistry, Dental School of Sao Paulo State University, 
      Araraquara, Sao Paulo, Brazil.
FAU - Gomes-Cornelio, Ana Livia
AU  - Gomes-Cornelio AL
FAU - Guimaraes, Felipe Coutinho
AU  - Guimaraes FC
FAU - Herrera, Bruno Schneider
AU  - Herrera BS
FAU - Bao, Sonia Nair
AU  - Bao SN
FAU - Rossa-Junior, Carlos
AU  - Rossa-Junior C
FAU - Guerreiro-Tanomaru, Juliane Maria
AU  - Guerreiro-Tanomaru JM
FAU - Tanomaru-Filho, Mario
AU  - Tanomaru-Filho M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120406
PL  - United States
TA  - J Endod
JT  - Journal of endodontics
JID - 7511484
RN  - 0 (Aluminum Compounds)
RN  - 0 (Calcium Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Oxides)
RN  - 0 (Root Canal Filling Materials)
RN  - 0 (Silicates)
RN  - 0 (mineral trioxide aggregate)
RN  - 91D9GV0Z28 (Durapatite)
MH  - Aluminum Compounds/chemical synthesis/chemistry/*pharmacology/toxicity
MH  - Analysis of Variance
MH  - Calcium Compounds/chemical synthesis/chemistry/*pharmacology/toxicity
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Crystallization
MH  - Drug Combinations
MH  - Durapatite/*chemistry
MH  - Humans
MH  - Materials Testing
MH  - Microscopy, Electron, Scanning
MH  - Osteoblasts/*drug effects
MH  - Oxides/chemical synthesis/chemistry/*pharmacology/toxicity
MH  - Root Canal Filling Materials/chemical synthesis/chemistry/*pharmacology/toxicity
MH  - Silicates/chemical synthesis/chemistry/*pharmacology/toxicity
MH  - Spectrometry, X-Ray Emission
MH  - Statistics, Nonparametric
MH  - Tooth Calcification/*drug effects
EDAT- 2012/06/19 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/19 06:00
PHST- 2011/12/23 00:00 [received]
PHST- 2012/02/21 00:00 [revised]
PHST- 2012/02/22 00:00 [accepted]
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S0099-2399(12)00212-9 [pii]
AID - 10.1016/j.joen.2012.02.018 [doi]
PST - ppublish
SO  - J Endod. 2012 Jul;38(7):971-6. doi: 10.1016/j.joen.2012.02.018. Epub 2012 Apr 6.